Novo wants to secure reputation through data access
Following increased public pressure the previously adamant drug industry has changed its tune, deciding to open its treasured clinical data vaults. But it is unlikely to result in crucial improvements for patients, says Novo Nordisk.
by Leonora Beck
In March the two drug companies AbbVie and InterMune sued the EMA because the agency wanted to publish “classified” and “commercially sensitive” data on the companies’ drugs. And in June a Sanofi executive, who is also head of the European industry organisation EFPIA, threatened to move investments out of Europe because he was dissatisfied with the latest demands for data access.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
